US 12,440,443 B2
Nano-emulsion of CBFβ-RUNX1 inhibitor for ocular drug deliver
Leo A. Kim, Brookline, MA (US); and Joseph F. Arboleda-Velasquez, Newton, MA (US)
Assigned to Massachusetts Eye and Ear Infirmary, Boston, MA (US)
Filed by Massachusetts Eye and Ear Infirmary, Boston, MA (US)
Filed on Feb. 1, 2023, as Appl. No. 18/163,041.
Application 18/163,041 is a continuation of application No. 16/763,932, granted, now 11,583,497, previously published as PCT/US2018/061156, filed on Nov. 14, 2018.
Claims priority of provisional application 62/586,027, filed on Nov. 14, 2017.
Prior Publication US 2023/0277454 A1, Sep. 7, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/107 (2006.01); A61K 31/5513 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/24 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01)
CPC A61K 9/1075 (2013.01) [A61K 31/5513 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/24 (2013.01); A61K 9/0048 (2013.01); A61K 9/19 (2013.01)] 20 Claims
 
1. A method for treating an ocular disease or condition in a subject in need of treatment for an ocular trauma or retinal detachment, the method comprising
topically administering, to an ocular tissue of the subject, a composition in the form of a nano-emulsion comprising a core binding factor β (CBFβ)-Runt Related Transcription Factor 1 (RUNX1) inhibitor,
wherein the ocular disease or condition is associated with aberrant ocular angiogenesis or comprises a proliferative ocular condition.